ADA Report. TECOS, sitagliptin. No increased cardiovascular risk and without negative effects on pancreas. juni 8, 2015 9:52 e m Läs mer »
ADA Report. New info to FDA from Medtr 640G, European user evaluation study, HbA1c reduced, insulin suspend delivery and insulin reduced juni 8, 2015 5:47 e m Läs mer »
ADA Report. GLP1-analog Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk. ELIXA study juni 8, 2015 4:55 e m Läs mer »
ADA Report. Launching Joint Statement and Guidance Document on Diabetes Self-Management Education and Support. Diab Care juni 8, 2015 4:45 e m Läs mer »
ADA Report Looking to the Future in Beta Cell Replacement and Transplantation juni 8, 2015 2:33 e m Läs mer »
